22 results
Approved WMOPending
To evaluate safety and feasibility of neoadjuvant chemotherapy-free regimen with trastuzumab, pertuzumab and tucatinib in stage II-III HER2-positive breast cancer.
Approved WMORecruiting
In the so-called adenocarcinoma of the esophagus, the HER2 receptor can be detected in about 15% of the tumors. Based on the phase II TRAP study performed in the Netherlands, we aim to demonstrate in this study that by adding trastuzumab and…